Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel impact on quality of life in metastatic prostate cancer
NL-OMON29025Not yet recruiting
- Start
- Feb 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of docetaxel in prostate cancer (PCa) and Metastatic Prostate Cancer (mPC) (3 cohorts), sponsored by none. Primary endpoint: Difference in change of quality of life by timing of docetaxel use. Planned start Feb 2021; status: not yet recruiting.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NL-OMON29025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29025.